| 000 | 01774 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250516181846.0 | ||
| 264 | 0 | _c20140818 | |
| 008 | 201408s 0 0 eng d | ||
| 022 | _a1932-6203 | ||
| 024 | 7 |
_a10.1371/journal.pone.0078856 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLatus, Joerg | |
| 245 | 0 | 0 |
_aCholestatic liver disease after rituximab and adalimumab and the possible role of cross-reacting antibodies to Fab 2 fragments. _h[electronic resource] |
| 260 |
_bPloS one _c2013 |
||
| 300 |
_ae78856 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAdalimumab |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAnti-Inflammatory Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Antineutrophil Cytoplasmic _xblood |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Humanized _xadministration & dosage |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal, Murine-Derived _xadministration & dosage |
| 650 | 0 | 4 |
_aCholestasis, Intrahepatic _xblood |
| 650 | 0 | 4 | _aCross Reactions |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin Fab Fragments _ximmunology |
| 650 | 0 | 4 |
_aImmunologic Factors _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMice |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aRituximab |
| 650 | 0 | 4 |
_aVasculitis, Central Nervous System _xblood |
| 700 | 1 | _aKlein, Reinhild | |
| 700 | 1 | _aKoetter, Ina | |
| 700 | 1 | _aSchwab, Matthias | |
| 700 | 1 | _aFritz, Peter | |
| 700 | 1 | _aKimmel, Martin | |
| 700 | 1 | _aAlscher, M Dominik | |
| 700 | 1 | _aBraun, Niko | |
| 773 | 0 |
_tPloS one _gvol. 8 _gno. 11 _gp. e78856 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1371/journal.pone.0078856 _zAvailable from publisher's website |
| 999 |
_c23277698 _d23277698 |
||